Clinical trial

Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

NCT07041450

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2025-03-14

PhaseN/A

Study timeline

Study start (actual)2025-03-14Date precision: day

Registry last updated2025-07-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Mild Cognitive Impairmentunresolved

Alzheimer Diseaseunresolved

Dementiaunresolved

Interventions

Digital MoCADIAGNOSTIC_TEST

XpressODIAGNOSTIC_TEST

MoCADIAGNOSTIC_TEST

Blood-based Biomarkers (BBM)DIAGNOSTIC_TEST

Amyloid Treatment Screening Tool (ATST)OTHER

MoCA Brain Health Questionnaire (MBHQ)OTHER

MoCA Medical QuestionnaireOTHER

Functional Activities Questionnaire+ (FAQ+)OTHER

Sponsors & collaborators

MoCA Clinic and Institutelead sponsor

C2N Diagnosticscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07041450 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.